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Summary 
Multiple myeloma is a B cell malignancy characterized by the expansion of plasma cells producing 
monodonal immunoglobulins (Ig).  It has been regarded as a tumor arising at  the B, pre-B 
lymphocyte, or even stem cell level. Precursor cells are presumed to proliferate  and differentiate 
giving rise to the plasma cell donal expansion. Antigenic features and specific  Ig gene rearrangement 
shared by B lymphocytes and myeloma ceils have supported this hypothesis. However, the existence 
of such a  precursor is based  upon indirect evidence  and is  still  an  open question.  During 
differentiation, B cells rearrange variable (V) regions of Ig heavy chain genes, providing a specific 
marker of clonality.  Using an anchor polymerase chain reaction assay, these rearranged regions 
from five patients with multiple myeloma were cloned and sequenced.  The switch of the Ig 
constant (C) region was used to define the B call differentiation stage: V regions are linked to 
C# genes in pre-B  and B lymphocytes (pre-switch B cells), but to C'I/or Cot in post-switch 
B lymphocytes and plasma ceUs (post-switch B cells). Analysis of bone marrow calls at diagnosis 
revealed the presence of pre-switch B ceils bearing plasma cell V regions still joined to the C/~ 
gene. These cells were not identified in peripheral blood, where tumor post-switch B cells were 
detected. These pre-switch B cells may be regarded as potential myeloma cell precursors. 
M 
ultiple myeloma is a B-cell malignancy characterized 
by a clonal expansion of plasma cells producing mono- 
clonal Ig. Several lines of evidence suggest B lymphocyte in- 
volvement in the pathogenesis of multiple myeloma. First, 
B lymphocytes, or even pre-B  lymphocytes expressing the 
same idiotype as myeloma protein have been found in bone 
marrow and peripheral blood (1-3). Second, malignant plasma 
cells expressing pre-B lymphocyte  antigens have been described 
(4-6). Third, PBMC may show the same IgH gene rearrange- 
ment as myeloma cells (7, 8). However, the existence of a 
myeloma cell precursor is still a subject of controversy (9, 10). 
Our molecular approach involved in the use of tumor cell 
IgH V region as a marker ofclonality. The antigen specificity 
in B lymphocyte clones is derived primarily from the rear- 
rangement of V, D, and J segments of H  chain genes. As- 
sembled variable regions (VDJ) contain three CDR that codify 
for the antigen-binding site. These regions are unique to each 
B cell done (11), and can be used to define oligonudeotide 
primers and probes characteristic of the tumor cell After an- 
tigenic stimulation, B lymphocytes switch the IgH isotype 
by deleting the C# gene, without changing the VDJ-encoded 
specificity Hence, pre-B  and B lymphocytes (pre-switch B 
cells) can be discriminated from post-switch B lymphocytes 
and plasma calls (post-switch B cells) because of their C re- 
gion usage. 
We reasoned that myeloma cell precursor may be located 
at the pre-switch B cell stage,  and be identifiable  as a cell 
in which the IgH transcript is composed of plasma ceU VDJ 
still joined to C# gene. The sequence of the plasma cell VDJ 
was obtained by using an anchor PCR assay (12), whereas 
the switch region was analyzed by means of a standard PCR 
protocol (13). 
Materials and Methods 
Patients andNucleic AcidExtraaion.  Four cases of multiple my- 
eloma were evaluated  at diagnosis and one at relapse. Two patients 
had an IgG (MM-20 and MM-23) and three an IgA (MM-15, MM- 
67, and MM-125) monoclonal protein. Specimens  were obtained 
during standard diagnostic procedures. Bone marrow plasma cells 
and lymphocytes  were separated  on a FicoU-Hypaque  density gra- 
dient. DNA was obtained by cell lysis, phenol extraction, and 
ethanol precipitation. RNA was isolated by the  guanidinium 
isothiocyanate and cesium chloride centrifugation method (14). 
Synthesis of  cDNA and Tailing Reaction.  Two syntheses  ofcDNA 
were performed: (a) total RNA was reverse transcribed using an 
isotype-specific  primer (c~ or 3/) to have the Ig cDNA; and (b) total 
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15 primer. 20 #g of total RNA was reverse transcribed with 20 
pmol of reverse  transcription primer (3:: GACCGATCW_W-,CCCTT- 
GGTGGAAGC [15], or ct: GACCTTGGGGC'IGGTCGGGGA- 
TGC [16]). A 50-/~1 reaction was carried out in 10 mM dithiothre- 
itol,  1 mM  dNTPs  (Pharmacia LKB  Biotechnology, Uppsala, 
Sweden), 1￿  reverse  transcriptase buffer (50 mM Tris-HCl, 6 mM 
MgClz,  40  mM  KC1), final concentration,  adding  20  U  of 
ribonuclease inhibitor  (ILNasin; Promega,  Madison, WI),  and 
400 U Moloney MuLV reverse transcriptase (Superscript, GIBCO 
BRL, Gaithersburg, MD). The reaction was incubated I h at 37~ 
The Ig cDNA was then tailed in 200/~M dATP, lx terminal deox- 
ynucleotidyl transferase (TdT) buffer, final concentration,  adding 
30 U of  TdT enzyme (GIBCO BRL), and incubated 10 min at 37~ 
PCR Conditions.  Three reactions were performed. The anchor- 
PCR assay (Fig. 1) included PCR-1 and -2, whereas PCR-3 was 
a standard amplification. For PCR-1, 20% of dA-tailed Ig cDNA 
was amplified  in 10% DMSO, 200 #M dNTPs, lx Taq buffer (50 
mM KC1, 10 mM Tris-HC1 pH, 8, 1 mM MgC12, 1% [wt/vol] 
gelatin) final concentration, adding 2.5 U of  Taq DNA polymerase 
(Perkin Elmer Cetus Corp., Norwalk, CT), 10 pmol of RE-TTTT 
(GGTGGATCGATGAATTCTTTTTTTTTTTTTTTTT), 20 
pmol of RE (GGTGGATCGATGAATTCTT),  and 20 pmol of  JH- 
RE2  (GGATGGTACCAAGCTTTGAGGAGACGGTGACCA) 
primers in a final volume of 50/~1. Using a DNA thermal cycler 
(Perkin Elmer Cetus Corp.)  the tailed cDNA was amplified by 
linking  two files together. File A: 94~  for 1 min;  50~  for 3 
min; 72~  for 40 min; 1 cycle. File B: 94~  for 1 min; 56~  for 
2 min; 72~  for I min; 40 cycles, followed by a 7-min final exten- 
sion at 72~  The 5' primers (ILE-TTTT, RE) contained ClaI and 
EcoRI restriction enzyme sites, whereas the 3' primers (JH-RE2, 
RE2) had KpnI and HindlII sites. The PCIL product was electro- 
phoresed on 1.5% low melting point agarose and the 500-bp band 
cut out under shortwave UV light.  For PCR-2,  the slice of low 
melting point agarose was melted at 68~  and 5-10% reamplified 
in the conditions described above, except for 2 mM MgC12 con- 
centration in the lx Taq buffer and 20 pmol of RE and RE2 primer 
(GGATGGTACCAAGCTTTGA),  instead of using RE-TTTT and 
JH-RE2. File C was used for this PCR: 94~  for 1 min; 54~ 
for 30 s; 72~  for 30 s; 32 cycles, followed by a 7-min final exten- 
sion at 72~  For PCR.-3, the amplification was used to detect the 
presence of clonal pre-switch B cells in bone marrow and periph- 
eral blood RNAs.  5 out of 50/~1 of total cDNA was amplified 
in the same PCR-2 conditions, except for the 1.5 mM MgCI2 con- 
centration in the lx  Taq buffer. The 5' primers were derived from 
CDKII, and were specific for each patient (Table 1), whereas the 
3' primer was from the C~ first exon (/~-1: GTTGGGGCGGATG- 
CACT [17]). File C was used at 61-64~  annealing temperature 
for 48-55 cycles. 
Oligonucleotide Synthesis.  Oligonucleotides were chemically  syn- 
thesized with a DNA synthesizer (model 391 PCR-MATE EP; Ap- 
plied Biosystems, Inc., Foster City, CA) on a 0.2-#mol scale, ac- 
cording to the manufacturer's instructions. 
Cloning and Sequencing.  The PCR product was digested with 
EcoRI and HindlII enzymes according to the manufacturer's in- 
structions  at 37~  for 3 h. Digested DNA was electrophoresed 
through a 1.5% low melting point agarose gel, the 500-bp band 
cut out, phenol/chloroform-extracted and precipitated in 2 vol of 
ethanol, and then cloned in a Bluescript SK  |  vector (Stratagene, 
San Diego, CA) according to standard procedures (14). Restriction 
enzyme analysis was carried out on plasmid DNAs prepared by 
the alkaline lysis method (14). Miniprep plasmid DNAs were se- 
quenced with the Sequenase  version 2.0 kit (United States Biochem- 
icals Corp., Cleveland,  OH) according to the manufacturer's recom- 
mendations. Sequence  analysis was performed using the PC-GENE 
programs (IntelliGenetics, Inc., Mountain  View, CA). 
Southern Blot and Direct Sequencing Analysis.  20% of the PCR 
product was analyzed  by agarose gel electrophoresis. The amplified 
DNA was blotted overnight onto nylon membranes (Stratagene), 
and hybridized to CDILIII  probes end-labeled with 3:[32P]ATP 
(14). 
The nucleotide sequence of the junction between the VDJ and 
C/~ genes was determined by direct sequencing of amplified DNA. 
5/~1 of  bone marrow total cDNA was amplified using CDRII and 
/~-5 (GGGAAT~AAGGAAGTCCTG'/GCGAG  [17]) primers./~-5 
is located 42 bp from/~-1 in the 3' direction. Amplification condi- 
tions were as described above. The CDRIII oligonucleotides (case 
MM-15 and MM-25) were also used as sequencing primers after 
end-labeling with 3:-[32p]ATP. Sequencing reactions  were  per- 
formed as previously described (18). Reaction products were run 
on a 6% acrylamide/urea gel, fixed in 10% acetic acid, and then 
exposed at  -70~  for varying periods of time. 
Results 
The anchor-PCR assay is outlined in Fig. 1 (19). Briefly, 
Ig cDNA was synthesized from bone marrow total RNA 
using primers specific for plasma cell C  region, and then a 
dATP tail was added by TdT enzyme to the 3' end. The dA- 
tailed Ig cDNA was amplified twice, using two sets of  primers 
0H-RE2, RE-TTTT, and RE, RE2). Finally, the amplified 
VDJ were cloned and sequenced. For each patient 10-20 clones 
were sequenced. The first sequencing gel analysis was per- 
Table  1.  Tumor-specific Primers and Probes 
CDP.II  CDRIII 
Patients  5' primer  Distance  probe 
MM-15  TTTCAGACCGAAGTCCGAGT  138 
MM-20  CTACATCAGTGGTACTGGTAATTC  126 
MM-23  CCTTTAGCAGATATGATCTC  124 
MM-67  ATAAGTGGAAGTGGCATTC  130 
MM-125  CGTGATGGGAGTAGTACAAG  136 
AGACTGAGGGCCAGTTGTTAC 
GGTCTCTCCCCATACTGACTA 
TTGTTTGGTGCGCATATCGG 
GGACGGGGAACTTGGATA 
GGACATAACAGTGGCTGG 
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Figure  1.  Schematic representation of the an- 
chor PCR assay. Bone marrow total RNA was re- 
verse transcribed into Ig cDNA using an isotype- 
specific primer (CH),  and then dA-tailed by TdT 
enzyme for anchor PCK. The tailed cDNA was 
amplified twice (PCRI/PCR2) by using two sets 
of primers (JH-RE2 with RE-TTTT, and RE and 
RE2).  The amplified VDJs were then cloned and 
sequenced. After sequencing analysis, the CDK 
were  identified  and tumor-specific primers  and 
probes were generated. 
Figure 2.  PCR-based detection of pre-switch B cells.  Detection of clonal 
pre- and post-switch  B cells in bone marrow and peripheral blood total 
cDNA of five myeloma patients. The amplifications were performed using 
CDRII 5' primer and different C region 3' primers. Amplified DNAs were 
then hybridized to CDRIII probes. (.4) MM-15 patient; (B) MM-20 pa- 
tient; (C) MM-23 patient; (D) MM-125; and (E) MM-67. Lane I, bone 
marrow total cDNA amplified with 3' or o~ primers; lane 2, empty; lane 
3, bone marrow total cDNA amplified with #-1 primer; lane 4, peripheral 
blood total cDNA amplified with/~-1 primer; lane 5, empty lane; lanes 
6 and 7, polyclonai cDNAs; and lane 8,  no DNA control. (F) lane a, 
MM-15 peripheral blood total cDNA amplified with ot primer; lane b, 
MM-20 peripheral blood total cDNA amplified with 3' primer; lane c, 
MM-23 peripheral blood total cDNA amplified with 3" primer; lane d, 
MM-125 peripheral blood total cDNA amplified with r  primer; and lane 
e, MM-67 peripheral blood total cDNA amplified with oe primer. 
formed to examine the 3' part of  the VDJ to assess how many 
clones were identical, and this number corresponded to the 
percentage of tumor cell infiltration in the specimen. A second 
analysis then gave the complete sequence of the three CDRs. 
The assay specificity was tested for each patient, generating 
clone-specific primers and probes from the CDR sequences. 
No amplification products were detectable when several poly- 
clonal DNAs were used as templates (19). However, further 
confirmation of myeloma specificity of the cloned VDJ se- 
quence was achieved by using the clone insert,  containing 
the supposed tumor VDJ, as a probe. Patient genomic DNA, 
was digested with HindlII restriction enzyme, and hybrid- 
ized under stringent conditions with this probe.  Southern 
blot analysis showed a rearranged band, confirming that the 
cloned VDJ really represented the tumor VDJ, and excluding 
any nonspecific bias during the amplification (data not shown). 
Bone marrow total RNAs from each patient were reverse 
transcribed in total cDNA,  and analyzed by using tumor- 
specific oligonucleotides to detect pre-switch B cells having 
the same plasma cell VDJ. Total cDNAs were tested for the 
presence of tumor CDRs  attached to the first exon of C# 
gene. A  PCR  amplification was carried out using CDRII 
and/~-1 primers. A second PCR was performed with 3' or 
r  3' primer to reveal post-switch B cells in the same cDNA. 
Then,  the amplified DNAs were hybridized to  a CDRIII 
probe.  All cases revealed  an intense band corresponding to 
the post-switch B cells,  amplified by the second PCR,  and 
one corresponding to pre-switch B cells bearing the C/~ gene 
(Fig.  2, A-E). To control the assay specificity, total cDNAs 
from two polyclonal LN were always used as a negative con- 
trols and no bands were detectable even after a long period 
of exposure. To further confirm Southern blot results, the 
bone marrow cDNA of MM-15  and MM-125  cases were 
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junction of the plasma  cell  VDJ with the C# sequence. (A) 
Schematic  representation  of primers used  in the amplification 
(CDRII,/z-5)  and sequencing  (CDRIII)  of  the VDJ-C/zjunc- 
tion. (B) After  the amplification  of  bone  marrow total cDNA 
(case MM-15, and MM-125), direct sequencing analysis 
showed the joining of the 3' end of plasma cell VDJ ~JH6 
andJH4) to the first exon (CHI)  ofC/~  gene. (Arrows)  Junc- 
tion point betweenJH6,  JH4, and CH1. G, A, T, C (dideox- 
ynucleoside triphosphates) represent the order of loading 
of the sequencing gel. 
reamplified using CDRII and/z-5  primers.  The use of #-5 
allowed the amplification  of a longer fragment  of C/z first 
exon. PCK products were then sequenced and the junction 
of tumor VDJ to the C# gene was definitively demonstrated 
(Fig.  3). 80 bp of the C# gene was read and showed a germ- 
line  configuration. 
Our analysis was also extended to the peripheral blood total 
cDNA samples.  The amplifications performed with CDRII 
and #-1  primers  did not  detect the presence of clonal pre- 
switch B cells.  Conversely, PCR reactions performed with 
CDRII and ot or 3' 3' primers revealed the presence of tumor 
post-switch  B  cells  (Fig.  2 F). 
Discussion 
The involvement of pre-B and/or B lymphocytes in mul- 
tiple myeloma has  been mainly deduced from the observa- 
tion that  they share some of the plasma cell antigenic  fea- 
tures  (1-5,  20)  and  that  myeloma-specific  IgH  gene 
rearrangements  take place in PBMC (7, 8). However, some 
technical aspects have prevented such involvement from ob- 
taining universal acceptance. For instance,  myeloma protein 
may nonspecifically bind to Fc receptors of PBL, which may 
then erroneously be recognized as neoplastic by anti-idiotypic 
antibodies (21). In addition, the specificity of these antibodies 
has been shown to be limited,  since they react with  more 
than one myeloma protein and also recognize several normal 
B cell clones (22, 23). Finally,  the presence in the peripheral 
blood of myeloma-specific IgH gene rearrangements has been 
ascribed to plasma cells (8, 9). For these reasons,  therefore, 
the B lymphocyte origin for multiple myeloma has thus been 
disputed,  and it  has  been regarded  as a tumor  originating 
at  plasma cell level. 
We devised an experimental strategy based upon the mo- 
lecular analysis of IgH genes. The CDRs provided a specific 
marker of clonality, whereas the presence of C/~ gene allowed 
the distinction  between pre-  and post-switch B  cells  (24). 
The hypothesis that a malignant  plasma cell derives from a 
pre-switch B cell implies the existence of a B cell in which 
the tumor VDJ is still joined to C# gene. We showed that 
the VDJ sequences identified by our assay represent the malig- 
nant plasma cell VDJ, and then we looked for a clonal pre- 
switch B cell population.  Analysis of bone marrow RNAs 
demonstrated the existence of such a population. Conversely, 
these pre-switch B cells were not found in the peripheral blood, 
where tumor post-switch B  cells  were detected.  It  should 
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could be too few to be detected by our assay. 
An IgH transcript in which the VDJ is still attached to 
C# sequences  can be mainly attributed to pre-B  and/or B 
lymphocytes, even though memory B lymphocytes  might be 
included. It has been reported that memory B lymphocytes 
may coexpress  C# and C3' or Ca genes (25,  26),  i.e., they 
can synthesize Ig molecules with different isotype linked to 
the same idiotype. The switch mechanism postulated for this 
finding is the alternative splicing of a large Ig RNA tran- 
script, and not the switch recombination characterized by 
C# gene deletion (for a review see reference  27). 
The bone marrow B cells carrying the tumor VDJ, and 
still expressing C# genes (pre-switch B cells), may be regarded 
as plasma cell precursors.  It should be pointed out, however, 
that our data do not provide a direct demonstration of malig- 
nancy, and do not exclude the existence of even more imma- 
ture precursors. The presence of peripheral blood cells in which 
the tumor VDJ sequences are linked to Ca or C3' genes (post- 
switch B cells) leads us to speculate  that these cells may be 
responsible  for the dissemination of the disease throughout 
the axial  skeleton. 
The contamination of tumor cells in peripheral blood is 
lower than bone marrow, and the apparent absence of pre- 
switch B cells in the peripheral blood indicates that it could 
be an alternative source  of normal stem cells for autograft 
procedures. 
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